Masterclass, Global Markets

Milford on AM 7 September 23

September 7, 2023

Dr Deborah Lambie Investment Analyst

Weight loss medication originally intended for diabetics is taking the world by storm, with demand outweighing supply. On AM, Investment Analyst Dr Deborah Lambie discusses two companies with outstanding product results – Novo Nordisk (Wegovy) and Eli Elly (Mounjaro). She looks into the reasons why their effectiveness, and explains why it might be a while before New Zealanders can have ready access to the drugs.

Latest Insights

Milford on Newstalk ZB: 18 December 2024

When to switch KiwiSaver providers

5 simple ways to kickstart your KiwiSaver in 2025

Disclaimer: Milford is an active manager with views and portfolio positions subject to change. This blog is intended to provide general information only. It does not take into account your investment needs or personal circumstances. It is not intended to be viewed as investment or financial advice. Should you require financial advice you should always speak to a Financial Adviser. Past performance is not a guarantee of future performance.